Product Data Sheet

SW2_110A

Cat. No.: HY-141716 Molecular Formula: $C_{42}H_{60}N_{6}O_{7}$ 760.96 Molecular Weight:


Histone Methyltransferase Target:

Pathway: **Epigenetics**

Storage: -20°C, protect from light, stored under nitrogen

* In solvent: -80°C, 6 months; -20°C, 1 month (protect from light, stored under

nitrogen)



SOLVENT & SOLUBILITY

In Vitro

DMSO: 125 mg/mL (164.27 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	1.3141 mL	6.5706 mL	13.1413 mL
	5 mM	0.2628 mL	1.3141 mL	2.6283 mL
	10 mM	0.1314 mL	0.6571 mL	1.3141 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (2.73 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (2.73 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (2.73 mM); Clear solution

BIOLOGICAL ACTIVITY

Description $SW2_110A is a selective chromobox\,8\,chromodomain\,(CBX8\,ChD)\,inhibitor\,with\,a\,K_d\,of\,800\,nM.\,SW2_110A\,shows\,minimal\,5-100\,chromobox\,8\,chromodomain\,(CBX8\,ChD)\,inhibitor\,with\,a\,K_d\,of\,800\,nM.\,SW2_110A\,shows\,minimal\,5-100\,chromobox\,8\,chromodomain\,(CBX8\,ChD)\,inhibitor\,with\,a\,K_d\,of\,800\,nM.\,SW2_110A\,shows\,minimal\,5-100\,chromobox\,8\,chromodomain\,(CBX8\,ChD)\,inhibitor\,with\,a\,K_d\,of\,800\,nM.\,SW2_110A\,shows\,minimal\,5-100\,chromobox\,8\,chromodomain\,(CBX8\,ChD)\,inhibitor\,with\,a\,K_d\,of\,800\,nM.\,SW2_110A\,shows\,minimal\,5-100\,chromobox\,8\,chromodomain\,(CBX8\,ChD)\,inhibitor\,with\,a\,K_d\,of\,800\,nM.\,SW2_110A\,shows\,minimal\,5-100\,chromobox\,8\,chromodomain\,(CBX8\,ChD)\,inhibitor\,with\,a\,K_d\,of\,800\,nM.\,SW2_110A\,shows\,minimal\,5-100\,chromobox\,8\,chromobox$ fold selectivity for CBX8 ChD over all other CBX paralogs in vitro^[1].

In Vitro

SW2_110A specifically inhibits the association of CBX8 with chromatin in cells and inhibits the proliferation of THP1 leukemia cells driven by the MLL-AF9 translocation (IC $_{50}$ of 26 μ M). In THP1 cells, SW2 $_{-}$ 110A treatment results in a significant decrease in the expression of MLL-AF9 target genes, including HOXA9^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES				
[1]. Sijie Wang, et al. Optimization of Ligands Using Focused DNA-Encoded Libraries To Develop a Selective, Cell-Permeable CBX8 Chromodomain Inhibitor. ACS Chem Biol. 2020 Jan 17;15(1):112-131.				
Caution: Product has not been fully validated for medical applications. For research use only.				
Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com				
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA				

Page 2 of 2 www.MedChemExpress.com